Hemoglobin SC Disease
10
0
0
4
Key Insights
Highlights
Success Rate
44% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
50.0%
5 terminated out of 10 trials
44.4%
-42.1% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Parent Educational Program for Children With Sickle Cell Disease
Treatment of Hemoglobin SC Disease With Hydroxyurea
Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)
Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
Safety Study of MP4CO in Adult Sickle Cell Patients
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate
A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders